drugset / Trial / NCT04430959

Candesartan as an Adjunctive Treatment for Bipolar Depression

NCT04430959

RandomizedCrossoverQuadruple-blindTreatment

Summary

This study will assess the safety and tolerability of Candesartan when used in patients with Bipolar Disorder, in addition to their medication treatment.

Timeline

Start
2020-10-01
Primary completion
2022-07-01
Completion
2022-09-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Candesartan Unknown 4 mg Oral

Indications